Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 trials. Gedatolisib shows promising efficacy and safety, especially in ...

RXRX's CDK7 inhibitor REC-617 has demonstrated activity but additional data from the ELUCIDATE trial in various solid tumors isn't expected until H2'25. Near-term catalysts include phase 2 TUPELO ...

Pyranopyrazole derivatives are a class of compounds that have garnered significant attention in medicinal chemistry due to their diverse biological activities, including anti-cancer, anti-malarial, ...

Incyte CEO Hervé Hoppenot has promised investors that 2025 will be “a year that will be full of many defining catalysts” for ...